Conclusion de l’atelier

• Tenir compte des recommandations ci-dessus en tant que guidelines
• Mise en place d’un comité d’experts. Porte d’entrée : registre France Greffe de Moelle (FGM) ; participants: membres du groupe de travail SFGM-TC
• Objectif: aide à la décision du choix du greffon de sang placentaire (SP) si besoin est exprimé par un centre greffeur
• Evaluation du suivi des recommandations par les centres greffeurs

Questions résiduelles à explorer

• Quelle dose cellulaire chez l’obèse ? adaptation sur poids idéal.
• Quand recruter l’USP de secours « back-up » ?
• Intérêt du typage élargi (niveau allélique classe I, HLA-C et DQ) NIMA
• Greffe phéno identique 9/10 vs greffe de sang placentaire ?
• Impact de la dose cellulaire et du type de conditionnement ?
• Evaluer l’impact de la compatibilité HLA entre les 2 USP

RÉFÉRENCES

1. Kamani N, Spellman S, Hurley CK, et al: State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 14:1-6, 2008

2. Rocha V, Gluckman E: Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147:262-74, 2009

3. Gluckman E: Ten years of cord blood transplantation: from bench to bedside. Br J Haematol 147:192-9, 2009

4. Michel G, Rocha V, Chevret S, et al: Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 102:4290-7, 2003

5. Laughlin MJ, Eapen M, Rubinstein P, et al: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265-75, 2004

6. Ballen KK: New trends in umbilical cord blood transplantation. Blood 105:3786-92, 2005

7. Eapen M, Rubinstein P, Zhang MJ, et al: Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369:1947-54, 2007

8. Wall DA, Chan KW: Selection of cord blood unit(s) for transplantation. Bone Marrow Transplant 42:1-7, 2008

9. Kurtzberg J, Prasad VK, Carter SL, et al: Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112:4318-27, 2008

10. Verneris MR, Brunstein CG, Barker J, et al: Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 114:4293-9, 2009

11. Kurtzberg J: Update on umbilical cord blood transplantation. Curr Opin Pediatr 21:22-9, 2009

12. Barker JN, Scaradavou A, Stevens CE: Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 115:1843-9

13. Brunstein CG, Gutman JA, Weisdorf DJ, et al: Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693-9

14. Schwabbauer ML: Use of the latent image technique to develop and evaluate problem-solving skills. Am J Med Technol 41:457-62, 1975

15. Barker JN, Byam C, Scaradavou A: How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 117:2332-9

16. Stevens CE, Carrier C, Carpenter C, et al: HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood 118:3969-78

17. Avery S, Shi W, Lubin M, et al: Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 117:3277-85; quiz 3478

18. McKenna DH, Brunstein CG: Umbilical cord blood: current status and future directions. Vox Sang 100:150-62

19. Broxmeyer HE: Insights into the biology of cord blood stem/progenitor cells. Cell Prolif 44 Suppl 1:55-9